Operating Company Healthcare

NAMSA

Toledo, Ohio, United States

NAMSA is the world’s leading medical device contract research organization (CRO), providing global end-to-end development services for medical device sponsors, including medical device testing, regulatory/reimbursement/quality consulting, and clinical research to support movement through the development lifecycle.

Focus Areas
Medical device testing, Regulatory consulting, Reimbursement and quality consulting
Website
namsa.com

Tracked deals

6

6 tracked deals across 2021-2025.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Addon

5 addon · 1 buyout

NAMSA Acquisition Volume by Year

Last 4 years

Acquisition volume by year Annual acquisition counts for the last 4 years for NAMSA. 3 2021 1 2022 1 2023 1 2025

Supporting Data

Recent Transactions

  • NAMSA Acquires WuXi AppTec U.S. Medical Device Testing Operations
    January 17, 2025
    Buyer
    NAMSA
    Target
    WuXi AppTec U.S. medical device testing operations
    Seller
    WuXi AppTec
    Industry
    Healthcare Services
    Location
    United States
    Type
    Addon

    NAMSA, an ARCHIMED-backed MedTech testing and clinical consulting firm, has acquired WuXi AppTec’s U.S. medical device testing operations (facilities in Minnesota and Georgia). The add-on expands NAMSA’s laboratory capacity and scientific capabilities across biocompatibility, microbiology, preclinical and extractables & leachables testing to better serve medical device manufacturers.

  • NAMSA Acquires SUAZIO
    March 27, 2023
    Buyer
    NAMSA, ARCHIMED
    Target
    SUAZIO
    Seller
    SUAZIO shareholders (including founder Christophe Van der Linden)
    Industry
    Healthcare Services
    Location
    Antwerp, Belgium
    Type
    Addon

    ARCHIMED-funded NAMSA has acquired SUAZIO, a Belgium-headquartered, data-driven life sciences and MedTech marketing and research consultancy. The add-on expands NAMSA's strategic consulting, market research and commercialization capabilities across medical devices and IVD markets; SUAZIO's founder reinvested proceeds and will continue to lead its consultancy services.

  • NAMSA Acquires Perfectus Biomed Group
    October 4, 2022
    Buyer
    NAMSA
    Target
    Perfectus Biomed Group
    Industry
    Medical Devices
    Location
    Cheshire, United Kingdom
    Type
    Buyout

    NAMSA, a global MedTech CRO headquartered in Toledo, Ohio, has acquired Perfectus Biomed Group, a UK-based microbiological testing laboratory headquartered in Cheshire. The acquisition expands NAMSA's European laboratory services and deepens its microbiological testing and biofilm expertise to better support medical device clients; terms were not disclosed.

  • NAMSA (ARCHIMED) Acquires Clinlogix
    August 2, 2021
    Buyer
    NAMSA, ARCHIMED
    Target
    Clinlogix
    Industry
    Healthcare Services
    Location
    Pennsylvania, United States
    Type
    Addon

    Toledo-based NAMSA, a portfolio company of healthcare-focused private equity firm ARCHIMED, has acquired Clinlogix, a Lower Gwynedd, Pennsylvania-based contract research organization (CRO) focused on medical device clinical trials. The deal expands NAMSA's clinical trial capacity by roughly 25%, deepens therapeutic expertise in neurology, oncology, urology and nephrology, and strengthens global trial capabilities with Clinlogix facilities in Japan, Germany and Colombia.

  • NAMSA Acquires American Preclinical Services (APS)
    March 2, 2021
    Buyer
    NAMSA, ARCHIMED (MED Platform I), Ares Management Corporation
    Target
    American Preclinical Services (APS)
    Industry
    Medical Devices
    Location
    Minnesota, United States
    Type
    Addon

    Toledo-based NAMSA, a medical-device-focused contract research organization owned by ARCHIMED's MED Platform I, has acquired Minneapolis-based American Preclinical Services (APS). The add-on expands NAMSA's lab, surgical instrumentation and imaging capabilities and increases its footprint in Minnesota; debt financing for the deal was provided by funds managed by Ares Management Corporation.

  • NAMSA Acquires Syntactx
    January 5, 2021
    Buyer
    NAMSA, ArchiMed
    Target
    Syntactx
    Seller
    Syntactx existing owners and management
    Industry
    Healthcare Services
    Location
    New York, United States
    Type
    Addon

    NAMSA, a medical device–focused contract research organization (and portfolio company of ArchiMed), has acquired New York–based CRO Syntactx. The add-on purchase expands NAMSA’s clinical research, electronic data capture (EDC), core lab imaging, safety and cardiovascular regulatory consulting capabilities to better serve global medtech sponsors.

Related Acquisition Pages

Healthcare Services Buyers & Acquisitions 4 tracked deals by NAMSA. Medical Devices Buyers & Acquisitions 2 tracked deals by NAMSA. Acquisitions in Minnesota 1 tracked deal by NAMSA. Acquisitions in New York 1 tracked deal by NAMSA. Acquisitions in Pennsylvania 1 tracked deal by NAMSA.

Related articles

Selling a company? Get in front of buyers like NAMSA

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →